secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2025-04-25T23:59:59+00:00
Accession:  0000950170-25-058776
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics presents preclinical data on SMARCA2 and KAT6A degraders at AACR
--------------------------------------------------------------------------------

- PRT3789, a selective SMARCA2 degrader in Phase 1/2, shows deep SMARCA2 degradation and high selectivity over SMARCA4.
- KAT6A degraders demonstrate robust anti-cancer activity in preclinical breast and lung cancer models, including complete regressions.
- Prelude's KAT6A degraders show reduced hematologic toxicity compared to dual KAT6A/B inhibitors, potentially improving safety.
- SMARCA2 resynthesis rate is 2-3 times slower than SMARCA4, contributing to broad therapeutic index of PRT3789.
- KAT6A degraders disrupt HAT complex and affect ERα expression, showing activity in ESR1- and PI3Kα-mutant and resistant cells.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017025058776/0000950170-25-058776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017025058776/prld-20250425.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-058776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer